No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AKRO Akero Therapeutics
- 22.380
- -0.780-3.37%
Close Jul 2 16:00 ET
- 22.380
- 0.0000.00%
Post 17:08 ET
1.55BMarket Cap-6907P/E (TTM)
23.210High22.230Low432.93KVolume23.030Open23.160Pre Close9.72MTurnover0.79%Turnover RatioLossP/E (Static)69.15MShares53.77052wk High1.83P/B1.23BFloat Cap11.25052wk Low--Dividend TTM54.75MShs Float58.380Historical High--Div YieldTTM4.23%Amplitude7.520Historical Low22.447Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Akero Therapeutics(AKRO.US) Officer Sells US$117.02K in Common Stock
$Akero Therapeutics(AKRO.US)$ Officer Young Jonathan sold 5,000 shares of common stock on Jul 1, 2024 at an average price of $23.404 for a total value of $117.02K.Source: Announcement What is statemen
Form 144 | Akero Therapeutics(AKRO.US) Officer Proposes to Sell 351.9K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Akero Therapeutics(AKRO.US)$ Officer Jonathan Young intends to sell 15,000 shares of its common stock on Jul 1, with a total market value of approximately $351.9K. Jo
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
Faruqi & Faruqi Logo (PRNewsfoto/Faruqi & Faruqi, LLP)
Express News | Cantor Fitzgerald Reiterates Overweight on Akero Therapeutics
CCORF Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $56
CCORF analyst Edward Nash maintains $Akero Therapeutics(AKRO.US)$ with a buy rating, and maintains the target price at $56.According to TipRanks data, the analyst has a success rate of 40.9% and a tot
Morgan Stanley Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $46
Morgan Stanley analyst Michael Ulz maintains $Akero Therapeutics(AKRO.US)$ with a buy rating, and maintains the target price at $46.According to TipRanks data, the analyst has a success rate of 40.8%
Comments
$Akero Therapeutics(AKRO.US$ whats going on it started going up again?
$Akero Therapeutics(AKRO.US$ Shitt stock
» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
7
$Akero Therapeutics(AKRO.US$ Im done with medical stocks not a single one of these companies can make good decisions
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg